• Event Type: The document is a transcript of the Q2 FY2027 Earnings Conference Call, which included a management presentation followed by a question-and-answer session with analysts.
  • Date and Time: The conference call was held on November 04, 2026. A specific start time was not mentioned in the transcript.
  • Purpose: The stated purpose of the call was to discuss the company's performance for the second quarter of FY2027, progress on strategic priorities, and the outlook for the remainder of the fiscal year.
  • Management Participants: The following management members participated:
  • Ms. Vinita Gupta – CEO, Lupin Limited
  • Mr. Nilesh Gupta – Managing Director, Lupin Limited
  • Mr. Ramesh Swaminathan – Executive Director, Global CFO & Head of IT and API Plus SBU, Lupin Limited
  • Mr. Ravi Agrawal – M&A and Investor Relations, Lupin Limited
  • Availability of Materials: The company stated that the transcript of the call is available on its website at www.lupin.com.
  • Financial Period Discussed: The call primarily discussed the financial and operational results for Q2 FY2027 (Quarter ended September 30, 2026) and the first half (H1 FY2027).
  • Forward-Looking Statements: Management provided extensive forward-looking commentary, including:
  • Reaffirmation of FY27 U.S. revenue guidance of USD 1.1 billion to USD 1.2 billion.
  • Reaffirmation of FY27 EBITDA margin guidance of around 24-25%.
  • Expectation of organic growth (ex-U.S.) of around 20% for the year.
  • Expectation for the India formulations business to grow at 1.2x to 1.3x the Indian Pharmaceutical Market (IPM) growth rate.
  • A plan to launch over 60 products in the U.S. over the next three years, including ~25 injectables and respiratory products, 5 biosimilars, and 2-3 505(b)(2) products.
  • Target for novel proprietary products to contribute one-third of India revenues within the next 10 years.
  • Expected effective tax rate (ETR) of 27-28% for FY27.
  • Expected R&D spend of ~8% of sales for FY27.

Additional Notes Section

  • The transcript was enclosed with a regulatory filing submitted to the BSE and NSE on November 06, 2026, signed by Amit Kumar Gupta, Company Secretary & Compliance Officer.
  • The document is a verbatim transcript of the earnings call, containing the full management presentation and the complete Q&A session with analysts.
  • No new unpublished price sensitive information (UPSI) was indicated to be shared during this call; it served as a discussion of already-disclosed results and publicly stated strategy.
  • Financial data from the quarterly results was discussed in detail, including revenues, margins, segment performance, and balance sheet items.
  • The call included discussions on specific products like Tolvaptan, Mirabegron, Apixaban Oral Suspension, biosimilars (Pegfilgrastim, Etanercept), and respiratory filings (Spiriva Respimat, Breo Ellipta).
  • Operational updates were provided on the remediation efforts at the Pithampur Unit II facility and the recent acquisition of VISUfarma.